Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study
| العنوان: | Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study |
|---|---|
| المؤلفون: | Penghai Zhang, Yinqiao Chen, Yongsheng Lin, Peizhen Zhu, Ruya Li, Jun Chen, Xiangwei Xu |
| المصدر: | World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-10 (2021) World Journal of Surgical Oncology |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Lung Neoplasms, Survival, RD1-811, medicine.medical_treatment, Maintenance therapy, Surgical oncology, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Chemotherapy, Stage (cooking), Lung cancer, Adverse effect, neoplasms, RC254-282, Retrospective Studies, Targeted drug, business.industry, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Retrospective cohort study, Prognosis, medicine.disease, respiratory tract diseases, Treatment Outcome, Adenocarcinoma, Female, Surgery, Advanced non-small cell lung cancer, business |
| الوصف: | Background The clinical efficacy and safety of maintenance therapy (MT) for patients with advanced non-small cell lung cancer (NSCLC) have not been determined in the real word. This retrospective study of real-world data analyzed these issues in patients with advanced NSCLC and stable or responsive tumors after 4–6 cycles of first-line chemotherapy. Methods We classified 158 patients into MT (34 IIIB and 37 IV stage) and non-MT (47 IIIB and 40 IV stage) groups and then compared the clinical outcomes of progression-free survival (PFS) and overall survival (OS). The influences of maintaining chemotherapy or targeted drugs, regimens, and duration on PFS were also investigated. Prognostic factors for OS were identified by univariate and multivariate analyses. Results Among the patients, 71 received MT and 87 did not. The median PFS and OS were significantly prolonged in the MT group than non-MT group (5.6 and 14.2 vs. 2.8 and 9.8 months, respectively; both p 4 cycles of chemotherapy, and targeted drugs for > 3 months (all P Highlights Maintenance therapy extended PFS and OS of patients with NSCLC.MT with targeted drugs significantly improved PFS compared with chemotherapy.Longer duration of MT with chemotherapy or targeted drugs prolonged PFS.Patients with adenocarcinomas and NSCLC without distant metastasis gained more OS benefits from MT.Female sex and MT were independent prognostic factors for extended OS.Patients with NSCLC tolerated MT without serious adverse events. |
| تدمد: | 1477-7819 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781ea5beba8726b2a9c82b6c815cba2b https://doi.org/10.1186/s12957-021-02340-0 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....781ea5beba8726b2a9c82b6c815cba2b |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14777819 |
|---|